Literature DB >> 34034718

Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.

Jia Peng1,2, Zhang Dong2, Zhang Hui1, Wang Aifei1, Deng Lianfu3,4,5, Xu Youjia6,7.   

Abstract

BACKGROUND: Wnt-catenin signaling antagonists sclerostin and dickkopf-related protein-1 (Dkk-1) inhibit bone formation and are involved in the pathogenesis of postmenopausal osteoporosis (PO). However, the association between sclerostin and Dkk-1 and bone mineral density (BMD) in women with PO remains unclear.
OBJECTIVE: This study aimed to determine the association between sclerostin and Dkk-1 and BMD, bone microarchitecture, and bone strength in PO.
METHODS: Trabecular bone specimens were obtained from the femoral heads of 76 Chinese women with PO who underwent hip arthroplasty for femoral neck fractures. Micro-computed tomography (Micro-CT) was used to assess the BMD and bone microarchitecture of the trabecular bone. Subsequently, a mechanical test was performed. Finally, sclerostin and Dkk-1 in the bone were measured by enzyme-linked immunosorbent (Elisa) assay. Serum ionized serum ionised calcium, propeptide of type 1 collagen, C-terminal β-telopeptide of type-1 collagen, sclerostin, and Dkk-1 were also detected.
RESULTS: Bone sclerostin was positively correlated with serum ionised calcium, serum sclerostin, BMD, bone volume/tissue volume (BV/TV), trabecular number (Tb.N), maximum compressive force, and yield strength (r = 0.32, 0.906, 0.355, 0.401, 0.329, 0.355, and 0.293, respectively, P < 0.05) and negatively correlated with age and trabecular separation (Tb.Sp) (r = - 0.755 and - 0.503, respectively, P < 0.05). Bone Dkk-1 was positively correlated with serum ionised calcium, serum Dkk-1, BMD, BV/TV, trabecular thickness, Tb.N, maximum compressive force, yield strength, and Young's modulus (r = 0.38, 0.809, 0.293, 0.293, 0.228, 0.318, 0.352, 0.315, and 0.266, respectively, P < 0.05) and negatively correlated with age and Tb.Sp (r = - 0.56 and - 0.38, respectively, P < 0.05). Serum levels of sclerostin and Dkk-1 reflected the levels of sclerostin and Dkk-1 in the bone.
CONCLUSION: Bone sclerostin and Dkk-1 were positively correlated with BMD in women with PO, and higher levels of bone sclerostin and Dkk-1 might predict better BMD, bone microarchitecture, and bone strength. The potential molecular mechanisms still require further study.

Entities:  

Keywords:  Bone microarchitecture; Bone mineral density; Bone strength; Dickkopf-related protein-1; Postmenopausal osteoporosis; Sclerostin

Mesh:

Substances:

Year:  2021        PMID: 34034718     DOI: 10.1186/s12891-021-04365-8

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  42 in total

1.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

2.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

Review 3.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

Review 4.  Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

Authors:  Maurizio Rossini; Davide Gatti; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

5.  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Jannis Kountouras; Polyzois Makras; Athanasios Papatheodorou; Panagiotis Kokkoris; Grigorios T Sakellariou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

6.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

7.  Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.

Authors:  Laia Gifre; Joan Vidal; Josep L Carrasco; Xavier Filella; Silvia Ruiz-Gaspà; Africa Muxi; Enric Portell; Ana Monegal; Nuria Guañabens; Pilar Peris
Journal:  J Bone Miner Res       Date:  2015-06       Impact factor: 6.741

8.  Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.

Authors:  Gary J Spencer; Jennifer C Utting; Sharon L Etheridge; Timothy R Arnett; Paul G Genever
Journal:  J Cell Sci       Date:  2006-03-07       Impact factor: 5.285

9.  The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.

Authors:  Jordan M Spatz; Marc N Wein; Jonathan H Gooi; Yili Qu; Jenna L Garr; Shawn Liu; Kevin J Barry; Yuhei Uda; Forest Lai; Christopher Dedic; Mercedes Balcells-Camps; Henry M Kronenberg; Philip Babij; Paola Divieti Pajevic
Journal:  J Biol Chem       Date:  2015-05-07       Impact factor: 5.157

Review 10.  Osteocyte-driven bone remodeling.

Authors:  Teresita Bellido
Journal:  Calcif Tissue Int       Date:  2013-09-04       Impact factor: 4.333

View more
  3 in total

1.  Vitamin D Supplementation for 12 Months in Older Adults Alters Regulators of Bone Metabolism but Does Not Change Wnt Signaling Pathway Markers.

Authors:  Marilena Christodoulou; Terence J Aspray; Isabelle Piec; Christopher Washbourne; Jonathan Cy Tang; William D Fraser; Inez Schoenmakers
Journal:  JBMR Plus       Date:  2022-03-24

Review 2.  New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1).

Authors:  Aylin Sepinci Dincel; Niklas Rye Jørgensen
Journal:  Calcif Tissue Int       Date:  2022-09-27       Impact factor: 4.000

3.  Clinical Data for Parametrization of In Silico Bone Models Incorporating Cell-Cytokine Dynamics: A Systematic Review of Literature.

Authors:  Charles Ledoux; Daniele Boaretti; Akanksha Sachan; Ralph Müller; Caitlyn J Collins
Journal:  Front Bioeng Biotechnol       Date:  2022-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.